Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102(24):8567-72. doi:10.1073/pnas.0503221102
Ferguson BS, Harrison BC, Jeong MY, et al. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2013;110(24):9806-11. doi:10.1073/pnas.1301509110
Moffett HF, Cartwright ANR, Kim HJ, et al. The microRNA miR-31 inhibits CD8 T cell function in chronic viral infection. Nat Immunol. 2017;18(7):791-799. doi:10.1038/ni.3755
Janouskova H, Tekle GE, Bellini E, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23(9):1046-1054. doi:10.1038/nm.4372
Khetarpal SA, Zeng X, Millar JS, et al. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017;23(9):1086-1094. doi:10.1038/nm.4390
Pomerantz MM, Li F, Takeda DY, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015;47(11):1346-51. doi:10.1038/ng.3419
Kim SY, Dunn IF, Firestein R, et al. CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS One. 2010;5(2):e8979. doi:10.1371/journal.pone.0008979
Corsello SM, Roti G, Ross KN, et al. Identification of AML1-ETO modulators by chemical genomics. Blood. 2009;113(24):6193-205. doi:10.1182/blood-2008-07-166090
Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet. 2007;39(5):673-7. doi:10.1038/ng2003
Finley LWS, Carracedo A, Lee J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization. Cancer Cell. 2011;19(3):416-28. doi:10.1016/j.ccr.2011.02.014